Table 1.
Participant demographics for the BEV group, BEV/pRDR group, and all participants combined
| BEV | BEV/pRDR | All | |
|---|---|---|---|
| Patients, n (%) | 47 (59) | 33 (41) | 80 (100) |
| OS Censored, n (%) | 8 (17) | 7 (21) | 15 (19) |
| Alive, n (%) | 2 (4) | 3 (9) | 5 (6) |
| Withdrawal, n (%) | 6 (13) | 4 (12) | 10 (13) |
| PFS censored, n (%) | 8 (17) | 7 (21) | 15 (19) |
| Progression free, n (%) | 0 (0) | 1 (3) | 1 (1) |
| Withdrawal, n (%) | 8 (17) | 6 (18) | 14 (18) |
| Age, median (range), y | 60 (23–79) | 42 (26–71) | 53 (23–79) |
| Male sex, n (%) | 28 (60) | 19 (58) | 47 (59) |
| KPS, median (range) | 70 (40–100) | 80 (60–100) | 70 (40–100) |
| Pre-BEV resection,* n (%) | 18 (38) | 14 (42) | 32 (40) |
| WHO grade III, n (%) | 12 (26) | 14 (42) | 26 (33) |
| WHO grade IV, n (%) | 35 (74) | 19 (58) | 54 (68) |
| Recurrences before | 1 (1–4) | 2 (1–4) | 1 (1–4) |
| BEV,† median (range) | |||
| >9 cycles of BEV before progression,‡ n (%) | 3 (6) | 3 (9) | 6 (8) |
| Treatment(s) after progression,§ n (%) | 24 (51) | 15 (46) | 39 (49) |
| Bevacizumab, n | 14 | 7 | 21 |
| Carmustine/ lomustine, n | 6 | 10 | 16 |
| With bevacizumab, n | 3 | 4 | 7 |
| Interferon, n | 1 | 0 | 1 |
| Isotretinoin, n | 9 | 3 | 12 |
| Pembrolizumab, n | 0 | 1 | 1 |
| Surgery, n | 2 | 0 | 2 |
| Tamoxifen, n | 1 | 0 | 1 |
| Temozolomide, n | 2 | 0 | 2 |
Abbreviations: max = maximum; OS = overall survival; PFS = progression-free survival; pRDR = pulsed reduced dose rate radiation therapy.
The number of participants who underwent surgical resection within 6 months prior to bevacizumab.
The number of tumor recurrences prior to bevacizumab.
The number of patients who continued bevacizumab at varied dosing and/or frequency beyond the standard full course while progression free.
The number of participants who received additional treatment after progression on either bevacizumab (BEV) or pRDR (BEV/pRDR). Tumor treating fields and other additional radiation therapy are not included because patients were censored from OS analysis when those therapies were initiated.